ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,507.53
0.15%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Century Therapeutics Inc (IPSC)

  7. Century Therapeutics Inc (IPSC) News

Century Therapeutics Inc

Century Therapeutics Inc (IPSC)

NASDAQ
2.88
-0.27
(-8.57%)
Closed April 28 4:00PM
Delayed by 15 minutes
2.88
0.00
(0.00%)
After Hours: 5:25PM
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

IPSC News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 08 2024
IPSC (-8.57%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
March 07 2024
IPSC (-8.57%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
March 06 2024
IPSC (-8.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 21 2024
IPSC (-8.57%)

Form 144/A - Report of proposed sale of securities: [Amend]
Edgar (US Regulatory)
February 21 2024
IPSC (-8.57%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 16 2024
IPSC (-8.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2024
IPSC (-8.57%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 07 2024
IPSC (-8.57%)

IPSC Discussion

View Posts
jondoeuk jondoeuk 2 weeks ago
Last year Clade Therapeutics announced the acquisition of Gadeta B.V. https://www.globenewswire.com/news-release/2023/10/02/2752753/0/en/Clade-Therapeutics-Announces-the-Acquisition-of-Gadeta-B-V.html

Gadeta was developing cell therapies expressing defined gamma-delta T-cell receptors that specifically recognise cancer cells. In order to harness the unique targeting properties of gamma-delta TCRs, Gadeta developed the TEG platform, which equips alpha-beta T-cells (used in the production of CAR and TCR therapies) with a defined gamma-delta TCR https://www.sciencedirect.com/science/article/pii/S0006497120448153

Gadeta also developed a novel proprietary gamma-delta TCR discovery engine based on a 'TCR centric' selection approach that sourced patient material (for a broad range of naturally selected gamma-delta TCRs from different tissues), screened (to identify tumour reactive gamma-delta TCRs from co-cultures of patient material) and selected gamma-delta TCRs optimal properties. Some preclinical data https://aacrjournals.org/cancerres/article/82/12_Supplement/2818/701504/Abstract-2818-Targeting-solid-tumors-with-GDT002-a
👍️0
jondoeuk jondoeuk 2 weeks ago
Upcoming (Fri, May 10) https://annualmeeting.asgct.org/program/agenda-speaker-details?agendaId=37279



As for the antibody degrader, I don't see them being able to combine the cells with therapeutic antibodies. But they might not need to add it.
👍️0
jondoeuk jondoeuk 2 weeks ago
Acquisition of Clade Therapeutics https://www.globenewswire.com/news-release/2024/04/11/2861378/0/en/Century-Therapeutics-Strengthens-Position-in-Autoimmune-Disease-with-Strategic-Pipeline-Expansion-Supported-by-60-Million-Private-Placement-and-Acquisition-of-Clade-Therapeutics.html

Some slides

👍️0
Monksdream Monksdream 4 weeks ago
IPSC under $5
👍️0
Lilman72003 Lilman72003 3 months ago
In 1.60
Out 4.35
👍️0
jondoeuk jondoeuk 5 months ago
Doesn't look that way with auto CAR-T. Out of the 15 treated, all had auto-antibodies, with 13 in skin, 11 in lung, 9 in kidney, 9 in joints, 4 in the heart, 3 in muscle, and other organs. Renal (kidney) disease occurs in up to 40% of patients and can evolve to kidney failure requiring dialysis and is associated with higher risk of death.

👍️0
NY1972 NY1972 5 months ago
CSO was smart selling off his shares. Depleting B cells is not investable, trading in SLE for B cell aplasia is a good deal?
👍️0
jondoeuk jondoeuk 5 months ago
Additional data https://century-therapeutics-initial-clinical-data-call.open-exchange.net/registration

Slides https://investors.centurytx.com/static-files/b88aac71-fffe-4b39-9573-82e3964f79b1
👍️0
jondoeuk jondoeuk 5 months ago
The PR https://www.biospace.com/article/releases/century-therapeutics-presents-initial-data-from-cnty-101-phase-1-elipse-1-trial-supporting-the-potential-for-a-multi-dosing-strategy-for-car-ink-enabled-by-allo-evasion-edits/

Poster https://www.centurytx.com/wp-content/uploads/2023-ASH-poster_Century-Tx_FINAL.pdf
👍️0
jondoeuk jondoeuk 5 months ago
Summary of the case that is going to be presented at ASH https://ash.confex.com/ash/2023/webprogram/Paper182313.html

Patient with high-risk R/R follicular lymphoma. Completed four 28-day cycles of CNTY-101 at the 100 million cell dose (DL1), first two administered following lymphodepletion, while the most recent two were administered without lymphodepletion. All doses of CNTY-101 with and without IL-2 or LD were well tolerated and demonstrated clinical benefit as defined as stable disease or better (per Lugano 2014 criteria). Responses were associated with tumour shrinkage and an ongoing CR of a duration of five months since the first CNTY-101 infusion. The PK data showed that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation. No measurable CDC-inducing functional ADA detected in any samples by data cut-off (including the first three cycles). Treatment was associated with changes in tumour microenvironment within eight days post-infusion, augmentation of adaptive T-cell responses, and tumour shrinkage.
👍️0
amateurtrader amateurtrader 1 year ago
CSO sold off his shares not sure why
👍️0
jondoeuk jondoeuk 1 year ago
Extensive epigenetic and transcriptomic donor-specific differences observed in iPSC derived allogenic NK (iNK) cells https://www.abstractsonline.com/pp8/#!/10828/presentation/6083

iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis https://www.abstractsonline.com/pp8/#!/10828/presentation/3328
👍️0
jondoeuk jondoeuk 1 year ago
Link to the webcast https://century-therapeutics-virtual-research-development-day.open-exchange.net/registration
👍️0
jondoeuk jondoeuk 1 year ago
The company will host a virtual Research and Development Day on Friday, Nov 11, from 8:00 AM to 9:30 AM ET. The R&D Day will feature presentations from the management team and Jonathan Rosenberg, M.D., Chief of the Genitourinary Oncology Service at the Memorial Sloan Kettering Cancer Center, Physician at Memorial Hospital, and Professor of Medicine at Weill Cornell Medical College. The event will focus on the company's solid tumour strategy and gamma delta iT cell platform, including a discussion on preclinical data to be presented at the Society for Immunotherapy of Cancer Annual Meeting.
👍️0
jondoeuk jondoeuk 2 years ago
SITC titles

Empowering iPSC-Derived iNK Cells with Multiple Gene Edits to Improve Persistence and Anti-Tumor Efficacy

Multiple Targeting of Solid Tumors with iPSC-derived Gamma Delta CAR T Cells in Combination with Therapeutic Antibodies
👍️0
jondoeuk jondoeuk 2 years ago
Yes, and the expansion cohorts will include both CAR-T naïve and relapsed. Next data from them should be around Dec, so ASH or an investor event. They have decided not to go past 1.5B cells per dose (x three doses) for some reason. Based on the data so far there is a dose response relationship (300M or 1B per dose) and all CRs are ongoing.
👍️0
jondoeuk jondoeuk 2 years ago
They should. High-affinity CD16 variants in the population correlate with clinical outcomes, so better objective responses and progression-free survival. However, the CD16 receptor is cleaved from the surface of activated NK cells, which leads to dysfunction and reduced antibody-dependent cellular cytotoxicity.

FATE could present some early clinical data on both at FT538 and FT536 at SITC. The former is being tested in combo with mAbs, while the latter (has an added CAR, along with the same three edits* as the other) is as a single agent or with mAbs.

* https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(21)00350-7
👍️0
NY1972 NY1972 2 years ago
NKTX seems to repeat what DTIL tried with 19a/eLD. Why they don't increase the NK cells dose to 4 billions same as AUTO NK?
👍️0
NY1972 NY1972 2 years ago
Will the ISPC NK cells work if the mAb is the weakest link? .AFM24 v. cetuximab hold the key to success?

AZ just stopped the trial of monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
👍️0
jondoeuk jondoeuk 2 years ago
Looking at P1 data from Fate and NKTX, NK cells seem to be effective on indolent lymphoma and nodal DLBCL.

FATE and NKTX have other trials ongoing in certain haematological malignancy. Adoptive transfer can induce long-term and durable remissions after a haploidentical stem cell transplantation in R/R AML. In those that are unable to undergo transplantation across seven published studies (over one hundred patients in total), 34% achieved a complete response to NK cell therapy alone. However, it has been demonstrated that the absence of NKGD2 ligand expression on leukemic stem cells determines therapy resistance and immune escape. PARP1 inhibitors can induce expression of NKG2D ligands, so I would like to see certain combo therapies https://www.nature.com/articles/s41586-019-1410-1

For pts with high tumor burden or aggressive disease, CART will still be needed.

Even for CAR-T, intensive debulking chemo could help those with a high tumour burden https://www.frontiersin.org/articles/10.3389/fonc.2021.706087/full

I listened to NKTX presentation, the number of cycles given to a patient will be up to the oncologist.

In June, NKTX filed a protocol amendment with the FDA for the ongoing PhI trial of NKX019 to optimise the trial's design as the company prepares for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide, in line with NKX101, and various expansion cohorts evaluating NKX019 in combination with rituximab. Also, three doses of CAR-NKs per cycle, with them currently enrolling a cohort testing 1.5 billion cells per dose.
👍️0
jondoeuk jondoeuk 2 years ago
According to a medical doctor on twitter they haven't been able to secure a source for the cbNKs. A second Fc receptor, CD64, binds to the same IgG's as CD16a, but with more than a 30-fold higher affinity. However, it is typically only expressed on myeloid cells, not NKs. FATE created a recombinant receptor consisting of the extracellular region of CD64 with transmembrane and intracellular regions of CD16a. Not only did they show activity, but additionally, the higher affinity of allowed for mAbs to be pre-adsorbed and improved targeting without additional mAb use. Also, they could still mix and match mAbs as well https://ashpublications.org/blood/article/136/Supplement%201/10/470430/Engineered-iPSC-Derived-NK-Cells-Expressing
👍️0
NY1972 NY1972 2 years ago
AFMD seemed to have solved the cleaved CD16 issue by pretreating the NK with their AFM13 ex-vivo.
👍️0
NY1972 NY1972 2 years ago
Looking at P1 data from Fate and NKTX, NK cells seem to be effective on indolent lymphoma and nodal DLBCL. For pts with high tumor burden or aggressive disease, CART will still be needed. I listened to NKTX presentation, the number of cycles given to a patient will be up to the oncologist.
👍️0
jondoeuk jondoeuk 2 years ago
Dr. Kaufman has presented some preclinical data

As for clinical, that comes from FATE and NKTX (using healthy donor), even though there are some differences between the programs in the same indications. From memory, in R/R NHL, FATE's best efficacy was achieved at a (much) lower dose (+/- rituximab), while NKTX had to go up to a billion across three doses (no rituximab).
👍️0
NY1972 NY1972 2 years ago
Has anyone compared ISPC NK to CBNK?
👍️0
jondoeuk jondoeuk 2 years ago
Slides https://investors.centurytx.com/static-files/f0d80de2-1e62-49b5-acfd-0e1388c58179
👍️0
jondoeuk jondoeuk 2 years ago
Link to webcast https://kvgo.com/corporate-services/century-therapeutics-rd-event
👍️0
jondoeuk jondoeuk 2 years ago
The poster https://www.centurytx.com/wp-content/uploads/2022/05/ASGCT22_Enabling-the-Engineering-of-iPSC-Based-Cell-Therapies-Using-MAD7-a-Novel-CRISPR-Nuclease.pdf
👍️0
jondoeuk jondoeuk 2 years ago
A virtual R&D update will be held on June 13, at 4:30 PM ET. Century's management will discuss CNTY-103 and progress on the next-generation platform. Dr Sheila Singh, Professor of Surgery and Biochemistry, Chief Paediatric Neurosurgeon at McMaster Children’s Hospital, the Division Head of Neurosurgery at Hamilton Health Sciences, and the inaugural Director of McMaster's new Cancer Research Centre will discuss the current treatment paradigm in GBM.
👍️0
jondoeuk jondoeuk 2 years ago
952: Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1867
👍️0
jondoeuk jondoeuk 2 years ago
ASGCT title:

Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease.
👍️0
jondoeuk jondoeuk 2 years ago
Preclinical data on mbIL-15 https://ashpublications.org/blood/article/124/7/1081/33687/Autonomous-growth-and-increased-cytotoxicity-of

NKG2A https://www.jci.org/articles/view/123955

PET https://jnm.snmjournals.org/content/61/9/1348.long

As for allo evasion, it could be CD47 https://rupress.org/jem/article/218/3/e20200839/211668/The-SIRP-CD47-immune-checkpoint-in-NK-cellsSIRP

👍️0
jondoeuk jondoeuk 2 years ago
Data Disclosures

MAD7 nuclease in iPSC gene editing platform (2Q).
Epigenetics and cell reprogramming (2H).
CNTY-102 (4Q).
iNK platform 2.0 (4Q).

Events

R&D Day (GBM, CNTY-103 and Universal CAR) (1H).
R&D Day (TBD) (4Q).
👍️0
jondoeuk jondoeuk 2 years ago
Posters https://www.centurytx.com/wp-content/uploads/2022/01/Induced-pluripotent-stem-cell-derived-?d-CAR-T-cells-for-cancer-immunotherapy.pdf https://www.centurytx.com/wp-content/uploads/2022/01/Development-of-Multi-Engineered-iPSC-Derived-CAR-NK-Cells-for-the-Treatment-of-B-Cell-Malignancies.pdf
👍️0
jondoeuk jondoeuk 2 years ago
PR https://www.globenewswire.com/news-release/2021/12/16/2353430/0/en/Century-Therapeutics-Announces-Presentation-of-Data-at-the-63rd-American-Society-of-Hematology-Annual-Meeting-and-Provides-Pipeline-Updates.html

Slides https://investors.centurytx.com/static-files/517375cf-023b-4926-bd42-a0e3e7e8708e
👍️0
jondoeuk jondoeuk 2 years ago
R&D Update (Dec 16, from 8:00 AM to 9:30 AM EST)

Link to webcast https://kvgo.com/corporate-services/century-therapeutics-r-d-2021
👍️0
jondoeuk jondoeuk 2 years ago
ASH abstracts

Development of Multi-Engineered iPSC-Derived CAR-NK Cells for the Treatment of B-Cell Malignancies https://ash.confex.com/ash/2021/webprogram/Paper148438.html

Induced Pluripotent Stem Cell-Derived Gamma Delta CAR-T Cells for Cancer Immunotherapy https://ash.confex.com/ash/2021/webprogram/Paper149095.html
👍️0
jondoeuk jondoeuk 3 years ago
They are also working on an iT (BCMA + undisclosed) for myeloma, iNK or iT (multi-specific) for bladder, iNK or iT (multi-specific) for ovarian, iNK or iT (multi-specific) for RCC, and iNK or iT (multi-specific) for HCC.
👍️0

Your Recent History

NASDAQ
IPSC
Century Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved